Dx&Vx, Oral Obesity Treatment Preclinical Candidate Synthesis Progress

DXVX announced on the 8th that it is focusing its capabilities on the development of an oral obesity treatment new drug.

DXVX is conducting research to develop next-generation oral GLP-1 obesity treatments and stated that it is synthesizing preclinical candidate substances with structural originality compared to existing developers.

The GLP-1 receptor agonist market is seeing injectable GLP-1 obesity treatments gain great popularity due to their strong weight loss effects, but there are high incidences of side effects such as pain, nausea, and diarrhea, which are drawbacks of the injection method.

The oral formulation being developed by DXVX is expected to increase patient satisfaction due to its convenient administration method and lower potential for side effects. Additionally, it is anticipated to have the same mechanism of action as existing injectable GLP-1 obesity treatments, which induce weight loss through appetite suppression and increased satiety, while addressing GLP-1 side effects such as muscle mass and metabolic rate reduction and gastrointestinal adverse effects.

Moreover, since it is being developed based on synthetic pharmaceuticals rather than peptide-based compounds, it is expected to enable broader treatment access, including easier administration routes and price reductions. The company is preparing for preclinical trials such as activity and efficacy tests of the candidate substances, as well as filing patents for its own compounds.

A DXVX representative said, “Currently, our sales department distributes and sells obesity treatments to hospitals and clinics nationwide, and we are also developing and selling our own microbiome-based branded diet probiotics series, so we have established a sales network for medical channels in the obesity and metabolic disease markets.” Therefore, “clinical trials have been completed at Rome Gemelli Hospital under the Italian Catholic Foundation, where microbiome strain analysis for obesity treatment and diagnosis is underway, and with the development of an oral synthetic obesity treatment new drug, Dx&Vx will ultimately grow into a leading company with a total solution for obesity prevention, diagnosis, treatment, and management.”

Meanwhile, the GLP-1 receptor agonist market is predicted to form a massive market exceeding 100 trillion KRW by 2030, and amid the soaring popularity of injectable GLP-1 anti-obesity drugs such as Zepbound and Wegovy, interest in the development of oral formulations is increasing.